Adverse drug reactions in neonates

Area of Science:

• Neonatal pharmacology
• Pediatric pharmacovigilance
• Drug safety in critical care

Background:

• Neonates are uniquely susceptible to adverse drug reactions (ADR) due to underdeveloped drug metabolism and elimination pathways.
• Critically ill neonates in intensive care units (NICU) often receive multiple medications, increasing ADR risk.
• Fetal drug exposure and percutaneous absorption of antibacterials have historical precedents for adverse events in newborns.

Purpose of the Study:

• To provide an overview of adverse drug reaction mechanisms in neonates.
• To review the incidence and specific examples of ADR in neonatal populations.
• To propose strategies for preventing and evaluating ADR in neonates.

Main Methods:

• Literature review of adverse drug reactions in neonates.
• Analysis of mechanisms underlying neonatal drug toxicity.
• Case examples and clinical experience with neonatal ADR.

Main Results:

• Adverse drug reactions, though uncommon, are a significant concern in neonatal intensive care units.
• Immature physiological systems, critical illness, polypharmacy, and fetal exposure contribute to neonatal ADR risk.
• Historical incidents highlight risks associated with certain drug classes, such as chloramphenicol (Gray Baby Syndrome) and systemically absorbed antibacterials.

Conclusions:

• Neonates require careful drug management due to their heightened vulnerability to adverse drug reactions.
• Understanding ADR mechanisms and specific neonatal risks is crucial for safe medication use.
• Implementing robust prevention and evaluation protocols can mitigate adverse drug events in this population.